Cardia Loop Series A

Medical device pitch deck, clearance path and unit economics

A device investor is buying two things at once: a regulatory calendar and a manufacturing cost. Cardia Loop is invented, and its ten slides put the 510(k) dates and the cost of one patch on their own slides rather than leaving either to the appendix.

Create a presentation with OneCraft10 slides, read in order

Every slide, in order

The whole deck as it renders, one slide after another. Read it the way the audience would.

CARDIA LOOP

SERIES A, 2027

A 14 day patch

IN ONE LINE

A single use adhesive patch that records a continuous heart rhythm for 14 days, posts itself back, and returns a cardiologist reviewed report in 48 hours. Cleared for sale, priced per episode, made for 96 dollars.

Arrhythmia monitoring that patients finish and clinics can afford

Marisol Tan

Co-founder and Chief Executive

Slide 1 · cover · Name the device and the claim in one line, with the clearance date on the cover.

The problem

Atrial fibrillation comes and goes. The standard test records for 24 to 48 hours, so it catches the rhythm only if the rhythm turns up on the day. Most of the time it does not, and the patient is sent home undiagnosed.

Three consequences

Short tests miss it

A 48 hour recording finds an arrhythmia in about a quarter of the people referred for one. The other three quarters are told nothing was found.

The referral repeats

A negative short test often becomes a second test months later, so the clinic pays twice and the patient waits twice as long for an answer.

Patients stop wearing it

Leads, a belt clip and a battery box are worn for two days at most. Nothing about that design survives a fortnight of showers and sleep.

02

Slide 2 · intro · The problem framed from the missed diagnosis rather than from the device market.

What Cardia Loop is

One patch, one prepaid envelope, one report. No app to install, no base station, no charger.

One adhesive patch

Applied in the clinic in under two minutes, worn for up to 14 days.

Continuous single lead trace

Every beat recorded to the patch, no streaming and no phone.

Posted back, prepaid

The patient drops it in a postbox. No return visit to the clinic.

Algorithm reads it first

The 14 day trace is reduced to the episodes worth a human look.

Cardiologist signs the report

A named cardiologist over reads and signs within 48 hours.

03

Slide 3 · pillars · What the product actually is, in five plain statements, so nobody asks what is in the box.

Holter monitor against the patch

Four measures, all of them from the pilot rather than from a brochure.

Holter, 48 hr

Cardia Loop

Wear time 48 hours

Two days of recording, and the belt box comes off for showers, so real wear is shorter again.

Yield 24 percent

About one in four referrals produces a finding. The rest end with no answer and a repeat referral.

Two clinic visits

One to fit the leads and one to return the box, both in working hours, both unpaid time off.

Cost 265 dollars

Device hire, technician fitting and the report, before the cost of the repeat test.

Wear time 14 days

Median completed wear in the pilot was 12.6 days, showers included, with one patch per patient.

Yield 61 percent

Six in ten referrals produced a finding, because the rhythm has a fortnight to turn up.

One clinic visit

Fitted at the appointment the patient already had, then posted back in the prepaid envelope.

Cost 380 dollars

One price for patch, analysis and signed report, with no second test in the pilot cohort.

04

Slide 4 · comparison · The patch against the incumbent test on the four things a cardiology clinic buys on.

The pilot, nine clinics

February to November 2026, every patch read by the algorithm and over read by a cardiologist.

1,240

Patients monitored

Across nine clinics in three states.

94%

Sensitivity

Against the cardiologist read of the same trace.

98%

Specificity

False positives fell as the cohort grew.

$380

Cost per episode

What a clinic pays, report included.

12.6

Median days worn

Out of a 14 day maximum wear.

61%

Diagnostic yield

A finding in six referrals out of ten.

05

Slide 5 · metrics · The pilot in six numbers, including the two a regulator will ask about.

The path to first sale

Five dated steps. Two are done, three are what this round pays for.

1

Sep 2026

Pre submission meeting held. Predicate agreed and the bench testing list fixed in writing.
2

Nov 2026

Pilot closed at 1,240 patients. Clinical data package assembled from nine sites.
3

Mar 2027

510(k) submitted, with adhesive biocompatibility and algorithm validation in the same file.
4

Jul 2027

Information request expected and budgeted. Ninety days of response time sits in the plan.
5

Dec 2027

Clearance expected, first commercial sale February 2028 into the nine pilot clinics.

Eleven months from submission to first sale

The information request is planned for, not hoped against

06

Slide 6 · process · The regulatory path with real dates, because a device with no clearance date has no plan.

How a clinic buys it

One patch, one report, two ways to pay for it. No hardware to buy and nothing to service.

Per patch

$380

per patient episode

Order one at a time, pay on the report

Patch, envelope and postage

Algorithm read plus over read

Signed report in 48 hours

Order a patch

Monitoring plan

$2,900

per month, up to 10 patches

For a clinic running ten or more a month

Ten patches, 290 dollars each

Same 48 hour report promise

Unused patches roll one month

Start a plan

07

Slide 7 · pricing · Two ways to buy the same patch, so a clinic sees the volume case beside the single episode price.

UNIT ECONOMICS

One patch, 380 dollars

Line
Per patch
Share
At 10,000 a year
Note
Price to the clinic
$380
100%
$3.80M
One price, report included
Patch build
$96
25%
$0.96M
Contract manufacturer, 5,000 unit runs
Cardiologist over read
$54
14%
$0.54M
Falls as the algorithm triage improves
Adhesive and postage
$18
5%
$0.18M
Prepaid return envelope included
Cloud analysis
$11
3%
$0.11M
Fourteen days of trace per patient
Clinic support
$22
6%
$0.22M
Fitting training and result queries
Contribution
$179
47%
$1.79M
Before sales and administration
Measured across the last 400 pilot patches. The over read is the largest single cost and the first to fall.

08

Slide 8 · metrics · Where the 380 dollars goes, so the margin question is answered before it is asked.

The ask

Enough to reach clearance, build the first 20,000 patches and sell into the clinics that already ran the pilot.

$8M

Series A, to clearance and the first year of manufacturing

$2.8M

Clearance and clinical

Thirty five percent. Bench testing, biocompatibility, the submission itself and the budgeted information request.

$2.4M

Manufacturing

Thirty percent. Adhesive tooling, a second assembly line and the first 20,000 patch build.

$1.9M

Commercial

Twenty four percent. Four clinical sales people and the over read panel, hired ahead of clearance.

$0.9M

Working capital

Eleven percent. Inventory sits for about 90 days between build and the report that gets paid.

09

Slide 9 · investment · The eight million split four ways, each tied to a step on the regulatory path.

Clearance December 2027

The pilot dataset, the submission index and the manufacturing quotes are in the data room on request.

Email

hi@cardialoop.example

Phone

+1 617 555 0139

Office

Somerville, MA

10

Slide 10 · closing · Close on the clearance date and leave three ways to get the submission file.

The structure

What each slide is doing, so you can reuse the order even with different content.

Slide 1cover
Name the device and the claim in one line, with the clearance date on the cover.
Slide 2intro
The problem framed from the missed diagnosis rather than from the device market.
Slide 3pillars
What the product actually is, in five plain statements, so nobody asks what is in the box.
Slide 4comparison
The patch against the incumbent test on the four things a cardiology clinic buys on.
Slide 5metrics
The pilot in six numbers, including the two a regulator will ask about.
Slide 6process
The regulatory path with real dates, because a device with no clearance date has no plan.
Slide 7pricing
Two ways to buy the same patch, so a clinic sees the volume case beside the single episode price.
Slide 8metrics
Where the 380 dollars goes, so the margin question is answered before it is asked.
Slide 9investment
The eight million split four ways, each tied to a step on the regulatory path.
Slide 10closing
Close on the clearance date and leave three ways to get the submission file.

Slide by slide

Slide one names the device and the claim in one line. Slide two frames the problem as a missed diagnosis rather than a market. Slide three lists what is in the box in five statements. Slide four compares the incumbent test with the patch on four buying measures. Slide five reports the 1,240 patient pilot in six numbers. Slide six is the regulatory path in five dated steps, two of them already done. Slide seven gives a clinic two ways to buy. Slide eight takes the 380 dollar price apart line by line. Slide nine splits the eight million ask across clearance, manufacturing, commercial and working capital. Slide ten closes on the clearance date and three ways to reach the founder.

How to adapt this deck

A device that needs a full premarket approval rather than a clearance moves the regulatory slide to third and doubles its length, because the calendar is then the main risk in the business. A diagnostic sold to laboratories rather than clinics swaps the pricing slide for a reimbursement slide, since the payer decides the price and the laboratory only decides the volume. A company already cleared and selling cuts the path slide to one line and gives the space to sales velocity, which is the number that replaces clearance as the thing being bought.

What this audience asks for

The United States regulator publishes what a premarket notification has to contain and how the review clock runs, and the Australian regulator publishes the equivalent for devices supplied here. Both are worth reading before a timeline slide is drawn, because both describe the point at which a reviewer can stop the clock and ask for more, which is the event most device timelines quietly omit. An investor who has funded devices before will look for that gap first, and a deck that has already put it on the chart does not have to defend the rest of the dates.

What makes this deck work

The information request is budgeted, not hoped against

Slide six puts an expected additional information request in July 2027 between submission and clearance, with 90 days of response time inside the plan. Every device founder knows it is coming. Putting it on the timeline is the difference between a schedule and a wish, and it is what makes December 2027 readable as a date.

The comparison uses pilot numbers, not brochure numbers

Slide four sets 48 hour monitoring against the patch on four measures, and the patch column comes from the pilot: 12.6 median days worn, 61 percent diagnostic yield. The subtitle says so. A comparison slide where only one side is measured is a claim with a table around it.

The margin is shown before it is asked for

Slide eight takes 380 dollars apart into six lines and lands on 179 of contribution at 47 percent, with the cardiologist over read named as the largest cost and the first to fall. Answering the margin question on your own slide is worth more than answering it well in the room.

Questions people ask

What is different about a medical device pitch deck?

Two slides that a software deck does not carry: the regulatory path with dates, and the cost to build one unit. Everything else is recognisable. This example gives each of those a full slide and puts the clinical pilot between them, because the pilot is what the submission rests on.

Where does the regulatory slide go?

After the clinical evidence and before the pricing. An investor has to believe the data before the dates mean anything, and has to believe the dates before the price is worth discussing. In this deck the pilot is slide five, the path is slide six and pricing is slide seven.

How much clinical detail belongs in the deck?

Enough to state sensitivity, specificity and the sample, with the clinic count and the dates. This deck uses six numbers on one slide. The full protocol, the statistical plan and the site list go in the data room, which the closing slide offers rather than promises.

Should I show unit cost to investors?

Yes. A device company is a manufacturing company, and an investor who cannot see the bill of materials will assume the worst. This example shows 96 dollars of build inside a 380 dollar price and names the line that falls with volume, which is the over read rather than the hardware.

How long should a device deck be?

Ten to twelve slides. This one is ten. The temptation is to add engineering detail, and the fix is to move it to an appendix that the technical diligence session uses. The main deck has to survive being read by a generalist partner in eight minutes.

What do I put on the pricing slide before clearance?

The price you intend to charge and the two shapes a buyer can take it in. This deck shows 380 dollars per episode and a 2,900 dollar monthly plan for ten. Pricing before clearance is a statement of intent, and saying so is better than leaving the slide out.

Build your own in about a minute

The button below opens the generator with this use case already described. Change the wording to match your own, generate, then edit anything you like.

Make one like this

Other presentation examples

Want the steps in the builder? Read Make a pitch presentation with AI, then Export a presentation to PowerPoint or PDF. For everything this generator can do, see the presentation maker.

Sources

Written and checked by the OneCraft team. Last checked .